See also this year's filing and all EDGAR filings for this company.
PDF Report 0001590750_2022_Viridian_Therapeutics_Inc_DE.pdf
Logs
| warning | The stock_price does not exist | industry.us_generic | {} |
| info | Failed to set obs_EconomicCapitalRatio | industry.us_generic | {'reason': "KeyError('stock_price')"} |
Graph
Absolute values for 0001590750, Viridian Therapeutics Inc DE
| xvar | xval | |
|---|---|---|
| 0 | IntangibleAssets | 0 |
| 1 | AssetsNonCurrent | 3,171,000 |
| 2 | AssetsCurrent | 200,163,000 |
| 3 | PropertyPlantAndEquipment | 375,000 |
| 4 | remainder_Assets | 0 |
| 5 | LongTermLiabilities | 1,208,000 |
| 6 | LiabilitiesCurrent | 13,636,000 |
| 7 | remainder_Liabilities | 1,149,000 |
| 8 | LaborExpense | 0 |
| 9 | CostOfGoodsAndServicesSold | 0 |
| 10 | GeneralAndAdministrativeExpense | 25,805,000 |
| 11 | GoodwillImpairmentLoss | 0 |
| 12 | OperatingCostsAndExpenses | 0 |
| 13 | DepreciationDepletionAndAmortization | 0 |
| 14 | SellingAndMarketingExpense | 0 |
| 15 | ResearchAndDevelopmentExpense | 0 |
| 16 | remainder_Expenses | 56,889,000 |
| 17 | remainder_Revenues | 2,963,000 |
| 18 | remainder_NetIncome | 318,000 |
| 19 | remainder_ComprehensiveNetIncome | -149,000 |
| yvar | yval | |
|---|---|---|
| 0 | Assets | 203,709,000 |
| 1 | Liabilities | 15,993,000 |
| 2 | Expenses | 82,694,000 |
| 3 | Revenues | 2,963,000 |
| 4 | StockholdersEquity | 187,716,000 |
| 5 | NetIncome | -79,413,000 |
| 6 | ComprehensiveNetIncome | -79,562,000 |
| 7 | BaseVar | 152,913,000 |
| 8 | EconomicCapitalRatiobeforeLimitedLiability | 1.75 |
| 9 | EconomicCapitalRatio | 2.21 |
Edgar->Model Mapping
Feature Distribution
Change over Time
